TrialInternational journal of chronic obstructive pulmonary disease2016

Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.

Craig LaForce et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.